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Abstract
Purpose—The purpose of this study was to examine the process of adolescent decision-making 
about participation in an HIV vaccine clinical trial, comparing it to adult models of informed 
consent with attention to developmental differences.
Methods—As part of a larger study of preventive misconception in adolescent HIV vaccine 
trials, we interviewed 33 male and female 16–19-year-olds who have sex with men. Participants 
underwent a simulated HIV vaccine trial consent process, and then completed a semistructured 
interview about their decision making process when deciding whether or not to enroll in and HIV 
vaccine trial. An ethnographic content analysis approach was utilized.
Results—Twelve concepts related to adolescents' decision-making about participation in an HIV 
vaccine trial were identified and mapped onto Appelbaum and Grisso's four components of 
decision making capacity including understanding of vaccines and how they work, the purpose of 
the study, trial procedures, and perceived trial risks and benefits, an appreciation of their own 
situation, the discussion and weighing of risks and benefits, discussing the need to consult with 
others about participation, motivations for participation, and their choice to participate.
Conclusion—The results of this study suggest that most adolescents at high risk for HIV 
demonstrate the key abilities needed to make meaningful decisions about HIV vaccine clinical 
trial participation.
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1. Introduction
Adolescents and young adults aged 13–24 accounted for 26% of new HIV infections in the 
United States in 2010 [1], and are therefore an important target for prevention. For legal and 
ethical reasons, HIV vaccine trials have predominantly enrolled adults [2,3]. However, 
inclusion of adolescents is essential in order for an efficacious vaccine to have an indication 
for use for minor adolescents. Enrolling minors in an HIV vaccine clinical trial poses a 
number of challenges, due to developmental, ethical and regulatory issues. Adolescents 
differ from adults in dimensions important to HIV [4], including relationship characteristics, 
sexual practices, needs for confidentiality, and family involvement [4–9]. Adolescence is a 
time of rapid development in cognitive capacity, with relevant differences from adults 
[10,11]. Other aspects of research decision-making in which adolescents may differ from 
adults include risk perception, willingness to accept risk, and decision making experience 
[12–15].
Because minors are considered a vulnerable population, adolescent HIV vaccine research 
presents complex regulatory challenges [16,17]. A core protection for all trial participants, 
particularly for research on sensitive topics [18], is informed consent. U.S. Federal 
regulations [19,20] typically use a parental permission/adolescent assent approach for 
minors who meet the definition of “children”, which is based largely on the assumption that 
parents will act in their children's best interests [16,21,22]. For research on sensitive topics, 
such as HIV, however, parental permission may introduce risk of harm, such as inadvertent 
disclosure of an adolescent's sexual orientation or HIV risk behaviors. In lower risk research 
on sensitive topics, best practice guidelines from the Society for Adolescent Health and 
Medicine recommend adolescent self-consent as an alternative to parental permission; for 
higher risk research, these guidelines recommend that investigators consider individual 
adolescents' capacity to consent [23].
The few existing data on adolescent clinical trial decision-making paint a mixed picture. 
One study found that some adolescents had difficulty with more complex trial concepts, 
such as randomization and false-positive tests [24]. Our own research showed that, 
generally, adolescents understood concepts such as placebo and clinical trial, but had more 
difficulty with the concept of randomization [25]. These studies focused on the outcome, 
rather than the process of the decision. The purpose of this study was to examine the process 
of adolescent decision-making about participation in an HIV vaccine clinical trial.
2. Methods
2.1. Participants and procedures
As part of a larger IRB approved study, we conducted qualitative interviews to elicit 
adolescents' understanding of an HIV vaccine clinical trial. Adolescents were recruited from 
four urban U.S. sites that were part of the Adolescent Medicine Trials Network for HIV/
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AIDS Interventions (ATN). Recruitment venues included youth groups, health clinics, and 
community events. Participants were sexually active 16–19 year old males (MSM) or 
females who had sex with males, were HIV-negative, and indicated a possible willingness to 
participate in an HIV vaccine trial. For the qualitative interviews, each site recruited 6–9 
participants from the larger quantitative study [26]. Informed consent was obtained from 
each participant, and parental consent was waived.
Participants underwent a simulated adolescent HIV vaccine trial consent process adapted 
from adult HIV vaccine trials. Adolescent participants were asked to read through the 
simulated HIV vaccine trial consent form, and then research staff walked participants 
through the information on purpose, procedures, risks, benefits and compensation, as if the 
participants were going to participate in an actual HIV vaccine trial. As part of the standard 
consent process, participants were given the opportunity to ask questions about the trial. 
Procedures were conducted by experienced ATN research staff – the very individuals who 
obtain consent for actual adolescent biomedical prevention trials. Following the consent 
process, all participants completed surveys, and a subset participated in qualitative 
interviews. This analysis focuses on the qualitative interviews.
2.2. Interviews
Semi-structured one-on-one interviews lasting 30–60 min were conducted by trained staff. 
Questions addressed the decision to participate in HIV vaccine trials, such as, “If an HIV 
vaccine clinical trial were available, would you participate? Why or why not?” Additional 
questions assessed the involvement of others in the decision-making process, risks and 
benefits of participation, and how risks and benefits played a role in the decision to 
participate (Fig. 1).
2.3. Analysis
Interviews were audio-recorded and transcribed. Data were analyzed using ethnographic 
content analysis [27], informed by a model of research decision-making from Applebaum 
and Grisso, that identifies four key tasks: (1) understanding relevant information about 
procedures, risks and benefits; (2) appreciating one's own situation and potential 
consequences of participation; (3) reasoning about options; and (4) communicating a choice 
[28–30]. This model has been used to inform assessments of capacity to consent among 
adults with psychiatric illnesses [31] and adults participating in HIV research [32].
Two researchers read transcripts, identifying codes surrounding the decision-making process 
used by adolescents. Data were analyzed using ethnographic content analysis, in which new 
codes were allowed to emerge from data during analysis, coding was iterative, and a 
consensus-based processes was used to resolve differences between coders. A preliminary 
model was created, and then tested and adjusted as subsequent transcripts were read, in an 
iterative manner. Disagreement between researchers was resolved through discussion. 
Detailed accounts of this coding process and the rationale behind each decision made were 
documented in a field journal.
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3. Results
3.1. Participants and overview of decision-making model
Thirty-three interviews were available for analysis. Demographics are in Table 1. We 
identified 12 concepts related to adolescents' decision-making about participation in an HIV 
vaccine trial. These concepts largely mapped onto Appelbaum and Grisso's four components 
of decision-making capacity [28,29], as depicted in Fig. 2. A complete list of model 
components and representative quotes can be found in Table 2.
3.2. Understanding relevant information
Most participants understood the purpose of the trial, procedures, risks and benefits (Fig. 2, 
Box 1). They demonstrated a range of understanding about the concept of a vaccine as 
preventative (see Table 2). Furthermore, we observed that understanding improved across 
the research interview, as adolescents reconsidered initial perceptions and understanding, 
and asked interviewers for additional information:
I: How do you come to that decision after you said before that maybe I wouldn't, 
but now I will, take it [the vaccine]?
A: Because based on how I think about vaccines and how I [thought] that they 
actually give you the [HIV] virus, and after reading about it and talking about it and 
being told that it won't give you that [the HIV virus], then I'm okay with it. (Male, 
16, Site 4)
Adolescents discussed three categories of perceived risks: effects of the vaccine, trial 
procedures, and stigma (see “Appreciate Own Situation” below). The most frequently 
discussed effects of the vaccine were physical side effects, followed by receiving a vaccine-
caused positive HIV test result if tested using an antibody test (the standard HIV screening 
test), and the potential for a breach of confidentiality. The possibility of testing positive for 
HIV outside of the research facility was highlighted in the simulated consent forms, and was 
a recurring point of discussion throughout the interviews. Many participants were unclear 
about what this positive result meant and how it would affect them, but most resolved this 
ambiguity through discussion with the interviewer. Although almost every participant 
mentioned the possibility of a positive test result, only six (out of 33) identified it as a 
concern specifically for themselves, citing psychological and emotional stress and the 
effects on romantic relationships and family members if they found out about the positive 
test results. Three adolescents were concerned with breach of confidentiality, but all stated 
they would participate in the HIV vaccine trial if it were available that day and would 
discuss participation with their mothers.
The only perceived risk related to trial procedures was receiving a shot, mentioned by two 
adolescents who reported being afraid of needles. A list of representative quotes can be 
found in Table 2, Section 1. Some trial procedures, such as the high number of visits (20 
visits) and the trial length (5 years) were considered inconveniences, but not risks. Older, 
male adolescents cited more time/commitment concerns, noting that they were at a point of 
transition in their lives and could not commit to something for 5 years because they did not 
know where they were going to be 5 years from now.
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Participants discussed both benefits to self (see “Appreciate Own Situation”), and benefits to 
others. The most frequently discussed benefit to others was helping others. For example, one 
adolescent stated,
“I think the benefits are, HIV is globally a big problem. I think we need to step 
towards vaccine. I think it's globally benefiting, not just benefiting me (Female, 17, 
Site 3).”
Another identified a contribution to the development of a possible HIV vaccine and saving 
lives.
3.3. Appreciate own situation (Fig. 2, Box 2 and Table 2, Section 2)
Most adolescents understood that participation in an HIV vaccine trial was research, not 
prevention (i.e., it was being done to learn something, rather than to give them early access 
to a vaccine). Additionally, most understood that they may not receive the actual vaccine as 
part of the trial and that it was not a treatment for HIV. A more detailed discussion of 
participants' understanding of the research concept of ‘experiment’ can be found elsewhere 
[25].
Personal risks and benefits showed more variation than risks and benefits specific to trial 
participation. It was evident that when discussing personal risks and benefits adolescents 
were actively considering their own situation and how the trial would affect them. The most 
commonly discussed personal risks specific to adolescent trial participation were the 
potential for a positive initial HIV test and stigma.
Two adolescents discussed the potential for a true positive HIV test results during the 
screening blood draw (i.e. finding out that they were already infected before the start of the 
trial) as a potential emotional risk for trial participation. Both of these adolescents were 19 
year old males who felt they were at an increased risk for acquiring HIV and knew people 
who were HIV positive.
The majority of adolescents discussed aspects of stigma as personal risks of trial 
participation, which included family suspicion that they were already HIV positive and 
discrimination on the job. For example, one adolescent stated:
“If your information got leaked that you were in the study, somebody might assume 
that you have HIV, so it's possible you can lose a job or your family could, I don't 
know how to put it, but your family might not agree with it, or they might treat you 
different as far as thinking that you have something (Female, 19, Site 1).”
Several adolescents were concerned about partner acceptance of their participation in the 
trial, indicating that their (potential) partners might not understand the positive HIV test 
result if they were to go with them to get tested at a facility outside of the trial facility. They 
felt their partners would think they either had HIV or were doing things that made them 
more likely to get HIV.
The most frequently discussed personal benefits were gaining information on HIV/AIDS 
followed by monetary compensation, access to a vaccine for HIV/AIDS prevention, and free 
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HIV testing. As a whole, adolescent participants stated they would still participate in the 
vaccine trial even if there were no monetary compensation. However, they did not believe 
other adolescents would participate without monetary compensation.
Adolescents who discussed monetary compensation as a benefit to trial participation tended 
to state their reason for participation without compensation was to prevent themselves from 
getting HIV. Those who did not state monetary compensation as a benefit tended to state 
‘helping others’ as their reason for participation without compensation. A list of personal 
benefits and example quotes can be found in Table 2, Section 2.
3.4. Reasoning about options (Fig. 2, Box 3 and Table 2, Section 3)
Most participants reported that they would discuss participation in an HIV vaccine trial with 
someone who could advise them on decision-making. The categories of individuals included 
(in order of decreasing frequency) were: peers, health care workers, family, and other adults. 
Only one participant stated that he would not talk to anyone before making the decision. 
Nine participants stated that even though they would talk to someone about the trial, that 
person's opinion was advisory only because they ‘make their own decisions.’ For example, 
when this adolescent was asked what role others would play in his decision, he stated,
“Just their opinion, that's it, because it's up to me if I'm going to decide to do it or 
not, just their opinion. (Male, 17, Site 3)”
The remaining 23 adolescent participants would involve at least one individual they 
identified as providing decision-making support (see “mother” in Table 2 Section 3).
While participants identified peers as the individuals they would most frequently talk to 
about joining the trial, health care providers were identified as the most influential, the most 
likely to sway their decision one way or the other. “My doctor” was the most frequently 
mentioned health care worker; reasons included (in decreasing frequency): (1) to make sure 
they were healthy enough to participate, (2) they trust their doctors, and (3) their doctors 
would be able to provide facts about HIV and HIV vaccines.
Mothers were identified as the most frequently consulted family members. Most of the 
adolescents who stated they would talk to their mother about an HIV vaccine trial were 
female and felt they would do so because they valued her opinion as their mother. Other 
reasons included the mother's knowledge of the medical field and because she has to drive 
them to appointments. A subset would talk to their mother out of respect, but that her 
opinion would not necessarily influence their decision. Of the adolescents who did not state 
they would discuss this decision with their mother, three specifically stated they would not 
consult their mother. Two of these adolescents were MSM and felt their mother would not 
understand why they wanted to participate in an HIV vaccine trial. The last was female and 
felt her mother had too much to worry about right then.
Six adolescents stated they would talk to an adult outside of their family and health care 
providers. Each of these adolescents was a young MSM, and none of them would have 
talked to a family member about the trial. Reasons for only consulting adults outside of the 
family included concerns that their family would not understand, might think they have 
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HIV, or would disapprove. See Table 2, Section 3 for individuals consulted and 
representative quotes.
3.5. Choice (Fig. 2, Box 4 and Table 2, Section 4)
All participants felt that the choice was theirs to make, and felt capable of making a choice. 
Consultation with peers, family and health care providers were characterized as useful for 
input, but not for the final decision regarding participation. The large majority of 
participants stated they would participate in an HIV vaccine clinical trial if one were 
available to them with fewer stating they were unsure or would not participate. Reasons for 
participation were consistent with the perceived benefits. Five adolescents were unsure if 
they would participate, citing concern about stigma, life being too unstable to make the 
commitment, and potential side effects. At the same time, these undecided adolescents still 
viewed participation as a way to ‘help others.’ Three said they would not participate in an 
HIV vaccine trial. Two of these participants felt the vaccine would not benefit them directly, 
while the other was concerned about unknown side effects.
4. Discussion
Among adolescents participating in a simulated consent process for participating in an HIV 
vaccine trial, we observed that most participants were able to comprehend relevant 
information about trial participation. Understanding trial purpose and procedures is a 
necessary component for informed consent [28,33]. Understanding was a process, and we 
observed that many adolescents who started the interview with a lower understanding level 
were able to resolve much of this misunderstanding through discussion with the interviewer 
[25]. Best practices for recruitment of adolescents will likely require an interactive process 
of assessing understanding and addressing misperceptions. Similar to previous research on 
adolescent capacity to consent to research [34,35], participants demonstrated to the 
interviewer that they were able to appreciate their own situation, logically manipulate 
information, and make a choice.
We found that adolescents were willing and interested in consulting with others about 
research participation, and placed particular trust in parents and health professionals. Even 
those that were planning on making their decisions on their own would consider the 
perspectives of trusted others. These findings are consistent with adolescent development. 
Adolescents are embedded in peer groups and families, are in a socially less powerful 
position compared to adults in their lives, and actively use role models and mentors in 
learning.
Finally, adolescent participants identified several issues related to HIV biomedical 
prevention trials that posed specific or increased risks to adolescents. The first was the 
distress related to a new HIV diagnosis made during baseline HIV testing. While a new 
diagnosis of HIV is distressing for individuals at any age, adolescents are particularly 
vulnerable because they have less access to health care and other resources, and heightened 
confidentiality concerns. The second was the high level of concern about stigma related to 
just participating in an HIV vaccine trial. Adolescents' vulnerabilities [36,37], including 
their financial and legal dependence upon families, increased confidentiality concerns. Their 
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position in society (in school, in entry-leveljobs) is more tenuous and dependent, putting 
them at increased likelihood of experiencing stigma. These vulnerabilities are heightened 
among adolescents at high risk for HIV, which include young MSM and adolescents in high 
poverty, low resource communities.
4.1. Limitations
While small sample sizes are necessary in qualitative research to gather information in 
sufficient detail, they also limit transferability of results to similar groups of adolescents. We 
recruited from the ATN as these are the adolescents that will most likely be recruited into a 
U.S.-based HIV vaccine clinical trial when one becomes available to them. A second 
limitation is that this interview was not a formal capacity assessment and should not be 
interpreted as such; instead it was a broader interview into the process of, and influences on, 
adolescent clinical trial decision-making.
The results of this study suggest that most members of this sample of adolescents at risk for 
HIV demonstrate the key abilities needed to make meaningful decisions about HIV vaccine 
clinical trial participation. These include the ability to understand the basic information 
provided to them, appreciate their own situation, consider information about risks and 
benefits of participation, consult with outside individuals and make a logical choice. These 
abilities can be supported through additional protections, such as additional efforts by HIV 
prevention researchers to assess adolescent understanding and address misperceptions, the 
judicious involvement of trusted adults selected by the adolescent to support them in the 
decision-making process, and attention to adolescents' situations, which may amplify 
concerns such as confidentiality and stigma.
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Fig. 1. 
Main questions from interview guide used for analysis of decision making among 
adolescents regarding participation in a hypothetical HIV vaccine trial.
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Fig. 2. 
Model of decision making among adolescents regarding participation in a hypothetical HIV 
vaccine trial.
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Table 1
Demographics.
Characteristic N (%)
Age
 16–17 years 18 (54.5%)
 18–19 years 15 (45.5%)
Race/ethnicity
 White, non-Hispanic 4 (11.1%)
 African American, non-Hispanic 21 (58.3%)
 Latino/Hispanic 4 (11.1%)
 Other 7 (19.4%)
Gender
 Male 19 (57.6%) – includes 1 transgender M → F
 Female 14 (42.4%)
ATN site
 Site 1 9 (27.3%)
 Site 2 9 (27.3%)
 Site 3 9 (27.3%)
 Site 4 6 (18.2%)
Recruitment venue
 Clinic 12 (36.4%)
 Community organization 12 (36.4%)
 Othervenue 9 (27.2%
Total 33 (100%)
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Table 2
Quotes representing components of decision making model.
Concept Quote
1. Understanding relevant information
Vaccine as prevention Limited understanding:
Interviewer (I): Would you get an HIV vaccine if it were available?
Adolescent (A): No, because I'm not HIV positive. (Female 16, Site 1)
Good understanding:
A: Not the ones who are already infected with HIV, already. It won't help them but it will help people 
that don't have HIV, protect them from getting the virus. (Female 18, Site 3)
Purpose I read that it was a basic, trial and error kind of thing to see if it will have a positive or negative effect on your 
body, to see whether or not they can use that as a possible HIV prevention in the future. (Male 19, Site 4)
Trial procedures Well, all your information is kept in to yourself. Everything is pretty much private, since you have - if you sign 
up for the research and stuff, it's pretty much you're helping to see - to find a vaccine for it, the HIV prevention. 
So, when you sign up for it, everything, you're just going to your appointments and stuff like that, to make sure 
everything's okay… You have like a 50–50 chance. One group will get it and the other group will not. One will 
get the placebo, one will get the vaccine. So it's like the flip of a coin. You really don't know who will get it. It's 
not decided amongst the doctors, or you can't decide if you're gonna be in group A or group B. It's like the flip 
of a coin. It could be heads or tails. (Male 18, Site 3)
Trial risks Well, a lot of stuff like I said, it's an experimental vaccine. So what actually happens to the human body when 
they give it to you, they're not 100% sure on what exactly it will do, whether it will make things better or 
worse. Whether it will prevent HIV or make chance of getting it higher. In the long run I could be screwing 
myself over. (Male 16, Site 1)
Trial benefits It could help. They could find some results off it and eventually come up with a vaccine for HIV that's open to 
the public, that maybe one day in the future somebody could go to a doctor who has HIV and get a vaccine for 
it. (Male 16, Site 1)
2. Appreciate own situation
Research versus treatment What I read about the HIV vaccine? I read about it was basically it's a vaccine; it's a research study. In the 
research study, you'll receive a placebo or the real thing, from what group you're in I guess. (Male 16, Site 1)
Personal risks Stigma Well, some people would question because they're just people. Why would you do something like that or do 
you have HIV or something (Female 18, Site 3)?
Testing positive There is that thought that you can possibly go to another HIV site and get tested and you can – your results 
could come back positive. That can be mind-blowing because who wants to be infected with HIV? Nobody… 
you wouldn't have it, but you would get a positive read if you were to go get tested somewhere else. Nine times 
out of ten, you'd get a positive read and that's the part of –you thinking, okay, well, I have HIV. (Male 17, Site 
3)
Personal benefits 
Information on HIV 
Monetary compensation
You learn more about it, of how to prevent HIV, to prevent from AIDS, everything, so that's why I'm looking 
at. (Female 17, Site 3) Also, another good thing is you're paid 75 dollars as well for your, I think for each visit 
if I remember. (Female 16, Site 2)
3. Reasoning about options
Weighing of risks and 
benefits
I feel like the consent form laid out very clearly what the pros and cons were. The main reason, motivation, 
why you participate in this study, as in finding a vaccine that prevents HIV, I think that's really important, and 
I'm really happy that that's there, that the study is there. I feel like that because you cannot get HIV through the 
vaccine, and the side effects seem relatively low or minimum, that it is really – yeah, that I consider the pros 
and cons, like the time that it would take, the health impact or not, and whether I could give HIV to other 
people or not, and it seems a safe study and well monitored as well. There are a lot of commitments that the 
subject needs to make, and I think that is really important to keep the study consistent but also the person, 
subject, safe. And then even though it may be a little bit of a hassle, the blood test, I feel like that it's really 
helpful to find out more information but also to make sure that the subjects stay safe. And so all those aspects 
together, I feel like I wanted to consider the study. (Male 17, Site 2)
Discussion of participation with others
Friends/family Doctor It would just be her opinion and I would take it into consideration out of respect…I make my own decisions. 
(Female 19, Site 1) A big one because of his status and his being educated about it, I think he could speak more 
off of facts instead of what he thinks than more statistics. I think by telling him the information that was 
provided to me, and then knowing his background information from his personal experience, that would help 
me with my decision a little bit more. (Female 17, Site 1)
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Concept Quote
Mother Yes, because she's a big part of my life. She's a big influence in my life so if she was to tell me no, I would 
listen to her and see why she's saying no and if it's for some of the same reasons, then I probably wouldn't. 
(Female 19, Site 4)
Considering motivations
Altruism Financial INT: What if there were no money involved in the trial. How would that affect the benefits to you?
R: I think I would still do it. I like helping people, so if participating in it would help to see if it really 
does work in the future, then I'd still do it. (Female 16, Site 1)
Medical benefit A: I would – I would say because of the fact that I'm one of those guys that's very sexually active and I 
think that would be something that's important for me to do.
I: So you would get the HIV vaccine so that you can continue your sexual activity?
A: Well not to just continue. Try to be on the safe side and, yeah. (Male 19, Site 3)
4. Choice
Yes Oh, because it would inform me – it would show me that while I participate, just because like I said, about me 
knowing that maybe I have a part in actually finding
HIV vaccine one day, and to inform other young adults that unprotected isn't okay, or whatever. And it informs 
us that just because we have this vaccine, that they're experimenting on this vaccine, don't go out and have 
unprotected sex, because it's not guaranteed that you wouldn't contract the HIV virus. (Male 16, Site 3)
Unsure Well, if I wanted, I would do it. Seeing how like I already read through a lot of the information and I've 
seen a lot of the risks and stuff, I'd most likely be willing to do it, but that's only if I wanted to – I still 
have mixed feelings about it…since there is a life-threatening allergic reaction that could happen, there 
might be other – they said there were unknown – other unknown side effects. (Female 17, Site 2)
I think there's a lot more factors that might contribute to whether or not I would or not. Would I be 
interested? Certainly but I'll go back to me being a youth and how unstable my life is right now. I 
wouldn't want to enroll in it if I didn't know if two months from now if I would still be able to do it. And 
I would like to but there's a lot of things contributing to whether or not I would do it, mostly with how 
unstable my life is and so I'd be very hesitant to do it. (Male 19, Site 2)
No I think I don't want to try the study because I don't want to have to go through all ofthe symptoms and you 
know, the risk of – you know, you never know what the pill or the shot will do to your body, but I'd just rather 
stay out of it, you know, because I don't want to pop up and it may be life threatening, you know? (Female 19, 
Site 3)
Vaccine. Author manuscript; available in PMC 2015 March 31.
